List of Excipients in Branded Drug BASIC CARE TIOCONAZOLE 1

« Back to Dashboard

Generic Drugs Containing BASIC CARE TIOCONAZOLE 1

Company	Ingredient	NDC	Excipient
L Perrigo Company	tioconazole	0113-7426	BUTYLATED HYDROXYANISOLE
L Perrigo Company	tioconazole	0113-7426	MAGNESIUM ALUMINUM SILICATE
L Perrigo Company	tioconazole	0113-7426	PETROLATUM

What are the Most Frequently-Used Excipients in BASIC CARE TIOCONAZOLE 1?

# Of NDCs	Excipient
1	BUTYLATED HYDROXYANISOLE
1	MAGNESIUM ALUMINUM SILICATE
1	PETROLATUM

Basic Care Tioconazole 1: Excipient Strategy, Regulatory Position, and Commercial Opportunities

Last updated: September 9, 2026

Basic Care Tioconazole 1 is an over-the-counter, single-dose vaginal antifungal containing tioconazole 6.5% in a vaginal ointment. Its commercial position depends less on active-ingredient exclusivity than on low-cost manufacturing, applicator performance, retail distribution, packaging, and consumer tolerability. The product is generally positioned as an interchangeable private-label alternative to branded tioconazole 1 products.

What is Basic Care Tioconazole 1?

Basic Care Tioconazole 1 is a vaginal antifungal product indicated for the treatment of vaginal yeast infections caused by Candida species. The product delivers one 6.5% tioconazole dose through a prefilled vaginal applicator.

Attribute	Product position
Brand	Basic Care
Active ingredient	Tioconazole
Strength	6.5%
Dosage form	Vaginal ointment
Regimen	One application
Therapeutic category	OTC vaginal antifungal
Primary indication	Vaginal yeast infection
Regulatory pathway	OTC drug monograph pathway
Likely commercial model	Private-label or store-brand equivalent
Main branded comparator	Vagistat-1 and other tioconazole 1 products
Biosimilar exposure	None
Orange Book patent listing	No standard Orange Book patent protection expected for the OTC monograph product

The FDA’s OTC vaginal antifungal monograph permits tioconazole at a 6.5% concentration for single-dose vaginal treatment, subject to labeling and formulation requirements.[1] The product does not depend on an innovator NDA with conventional small-molecule exclusivity.

What excipients are used in Basic Care Tioconazole 1?

Public labeling for tioconazole 6.5% vaginal ointment identifies a simple excipient system consisting of mineral oil, purified water, and benzoic acid.[2]

Excipient	Functional role	Commercial significance
Mineral oil	Oily vehicle and emollient	Supports vaginal residence, lubrication, and drug dispersion
Purified water	Aqueous phase	Enables a semisolid emulsion-type system and controls texture
Benzoic acid	Preservative and formulation aid	Supports microbiological control and product stability

The excipient system is intentionally narrow. A small composition reduces raw-material cost, simplifies supply qualification, and limits the number of variables affecting drug release and patient tolerability.

Mineral oil as the primary vehicle

Mineral oil provides the product’s lubricating and occlusive character. It helps maintain a semisolid dose after administration and can extend local contact with vaginal tissue. The same property creates commercial constraints:

• The product may feel greasy compared with water-based creams.
• Oil can create leakage or residue after administration.
• Compatibility with condoms and contraceptive devices must be addressed in labeling.
• Packaging materials must resist extractables, leachables, and loss of product through the applicator.

For a private-label product, mineral oil is commercially attractive because it is inexpensive, widely available, and pharmaceutically familiar. A supplier change can still affect viscosity, hydrocarbon distribution, odor, and product appearance.

Purified water and emulsion control

The presence of purified water creates a formulation-control requirement that anhydrous ointments would not have. The manufacturer must control:

• Phase distribution
• Droplet size
• Viscosity
• Water activity
• Microbial quality
• Freeze-thaw stability
• Drug-content uniformity

A product that separates during storage can show inconsistent dosing and poor consumer acceptance. The formulation therefore requires more process control than a simple oil-only ointment, even though its excipient list is short.

Benzoic acid and preservation

Benzoic acid supports preservation and can contribute to pH control. Its concentration and distribution affect antimicrobial performance, irritation potential, and long-term stability. Commercial development opportunities include improving preservative robustness while avoiding unnecessary excipients that could increase burning, itching, or sensitization.

What formulations are protected by the tioconazole 1 excipient strategy?

The basic tioconazole 1 formulation is not known to have meaningful current exclusivity based on its excipients. Mineral oil, purified water, and benzoic acid are established pharmaceutical ingredients, and the product is sold under an OTC monograph framework rather than a patent-dependent NDA model.

Potentially protectable formulation attributes could include:

1. A narrowly defined rheology profile that improves vaginal retention.
2. A specific emulsion or microstructure that controls tioconazole release.
3. A low-irritation preservative system.
4. An applicator-and-formulation combination that reduces leakage.
5. A packaging system that improves dose delivery and stability.
6. A formulation compatible with selected barrier contraceptives.

A generic formulation patent would require more than the presence of conventional excipients. It would generally need a non-obvious composition or performance result, supported by comparative data. A standard mineral oil, water, and benzoic acid vehicle would face a substantial obviousness risk if asserted broadly.

What is the FDA regulatory status of Basic Care Tioconazole 1?

The product is regulated as an OTC vaginal antifungal. The FDA monograph pathway allows compliant products to be marketed without an individual premarket approval application, provided the active ingredient, strength, dosage form, labeling, and other conditions meet the applicable monograph requirements.[1]

FDA requirements affecting excipients

The excipient system must support compliance with several requirements:

• Drug identity and strength
• Uniformity of the single dose
• Stability through labeled shelf life
• Microbiological quality
• Appropriate container-closure performance
• Compatibility with the vaginal route
• Accurate Drug Facts labeling
• Manufacturing under current good manufacturing practice requirements

The formulation cannot be evaluated only on ingredient cost. A low-cost preservative or vehicle change can require stability, microbial, compatibility, and consumer-use assessments.

What is the Orange Book status of Basic Care Tioconazole 1?

Basic Care Tioconazole 1 is not expected to have the same Orange Book patent framework as an approved prescription NDA product. OTC monograph products generally do not rely on listed patents for market exclusivity, and the relevant product does not have a conventional innovator exclusivity position comparable to a prescription drug.[3]

Exclusivity issue	Assessment
New chemical entity exclusivity	Not applicable
Prescription NDA exclusivity	Not applicable
Pediatric exclusivity	Not applicable
Orange Book patent listing	No standard listing expected
OTC monograph protection	Applicable regulatory framework
Formulation patent risk	Possible in theory, but no established estate identified from the public product position
Market-entry barrier	Manufacturing, quality, distribution, branding, and retail access

When does tioconazole 1 lose exclusivity?

Tioconazole 1 has no meaningful active-ingredient exclusivity remaining. Tioconazole is an established antifungal, and the 6.5% single-dose vaginal product is available through the OTC market.

The relevant commercial question is therefore not when exclusivity expires. It is whether a competitor can produce a compliant product at a lower cost or win shelf space through better packaging, price, consumer reviews, or pharmacy distribution.

Are Paragraph IV challenges relevant?

A conventional Paragraph IV challenge is generally not the primary pathway for a competing OTC monograph product. Paragraph IV litigation is associated with abbreviated new drug applications that certify against listed patents in the Orange Book. A competing manufacturer can instead formulate and market a compliant OTC product under the applicable monograph, subject to FDA and manufacturing requirements.

A Paragraph IV strategy could become relevant only if a company pursued an NDA or ANDA product tied to listed patents. That is not the normal route for a standard tioconazole 6.5% OTC product.

What patent litigation affects Basic Care Tioconazole 1?

No prominent current patent litigation is associated with the standard Basic Care Tioconazole 1 product position. The principal legal risks are more likely to involve:

• Trademark or trade-dress disputes
• Labeling and advertising claims
• Product liability
• Manufacturing defects
• Consumer class actions involving leakage or irritation
• Alleged noncompliance with OTC monograph requirements
• Supplier or contract-manufacturing disputes

The absence of active-ingredient patent protection increases the importance of operational compliance. A competitor can enter without waiting for a patent expiration date, but it must meet the same quality and labeling standards.

How strong is the tioconazole 1 patent estate?

The patent estate is weak as a barrier to ordinary OTC competition.

Patent dimension	Relative strength
Active ingredient	Weak; mature molecule
6.5% strength	Weak; monograph-recognized strength
Single-dose regimen	Weak; commercially established presentation
Mineral oil vehicle	Weak; conventional excipient
Benzoic acid preservation	Weak; conventional use
Applicator configuration	Moderate only if technically differentiated
Advanced release-control formulation	Potentially stronger
Packaging and delivery system	Potentially protectable, but narrow
Manufacturing process	Potentially protectable if process-specific and non-obvious

A stronger future patent strategy would focus on measurable product performance rather than ingredient identity. Examples include reduced leakage, improved dose retention, improved delivery uniformity, lower irritation, or compatibility with specified contraceptive products.

What commercial opportunities exist for excipient innovation?

The strongest commercial opportunities are incremental rather than molecule-based.

Lower-irritation formulations

Some consumers report burning, itching, or discomfort after vaginal antifungal treatment. A reformulation opportunity could involve reducing excipient-related irritation while preserving tioconazole release and microbial control.

Potential approaches include:

• Optimizing benzoic acid concentration
• Adjusting pH
• Selecting higher-purity mineral oil
• Reducing odor and residue
• Replacing or supplementing the preservative system
• Developing a more uniform emulsion

Any reformulation would require evidence that the new excipient system maintains drug performance and microbiological quality.

Improved retention and reduced leakage

Leakage is a material consumer-experience issue for vaginal ointments. A product with better vaginal residence could support premium pricing if it demonstrates:

• Lower post-dose leakage
• More consistent tissue coverage
• Improved patient confidence
• Lower need for repeat application
• Better applicator control

A rheology-modified formulation could create patentable subject matter if it produces a demonstrated clinical or in-use benefit.

Water-based or lower-residue alternatives

A water-based gel, cream, or bioadhesive system could compete with the traditional oily ointment. The main development challenges would be:

• Tioconazole solubility or dispersion
• Drug release
• Preservative efficacy
• Vaginal pH
• Osmolality
• Applicator filling
• Stability
• Patient tolerability

A successful water-based product could appeal to consumers who dislike oily residue, but it would face greater formulation complexity than the conventional mineral-oil vehicle.

Packaging and applicator improvements

The applicator is a practical source of differentiation. Opportunities include:

• Tamper-evident unit-dose packaging
• Improved plunger control
• Reduced residual product in the applicator
• Less mess during administration
• More comfortable insertion geometry
• Applicators made from recyclable or lower-cost materials
• Packaging designed for discreet transport

These improvements may be protectable through utility or design rights, although their commercial value depends on whether consumers recognize the benefit.

How does Basic Care Tioconazole 1 compare with competing vaginal antifungals?

Product type	Typical regimen	Main commercial advantage	Main limitation
Tioconazole 1	One dose	Highest convenience	Oily residue and leakage
Clotrimazole 1-day	One dose	Broad consumer familiarity	Formulation and irritation differences
Miconazole 1-day	One dose	Strong retail presence	Oily or messy delivery depending on product
Miconazole 3-day	Three doses	Alternative tolerability profile	Lower convenience
Miconazole 7-day	Seven doses	Longer local treatment	Adherence burden
Oral fluconazole	One oral dose by prescription in many markets	No vaginal administration	Systemic exposure and prescription requirements

Basic Care’s most important competitive benchmark is not a patented product. It is the price and consumer experience of other one-dose vaginal antifungals.

Which companies are challenging the tioconazole 1 market?

Competition comes from private-label retailers, generic OTC manufacturers, and branded vaginal antifungal companies. Relevant competitive groups include:

• Amazon or retailer-controlled private-label products
• Perrigo and other OTC contract manufacturers
• Branded manufacturers selling tioconazole products
• Manufacturers of miconazole and clotrimazole products
• Pharmacy chains and mass retailers offering store brands

The market is suitable for multiple suppliers because the active ingredient is mature and the regulatory pathway is relatively standardized. Retailer purchasing power can shift volume rapidly between manufacturers.

What generic launch risks exist?

Generic and private-label entry is technically feasible, but several risks remain.

Manufacturing risks

• Nonuniform filling of viscous ointment
• Separation of the aqueous and oil phases
• Applicator leakage
• Inconsistent dose weight
• Stability failure under heat exposure
• Microbial contamination
• Container-closure incompatibility

Regulatory risks

• Incorrect Drug Facts language
• Failure to meet monograph conditions
• Unsupported comparative claims
• Inadequate stability data
• Inadequate process validation
• Packaging that does not protect product quality

Commercial risks

• Retailer price compression
• Low brand loyalty
• Consumer preference for established brands
• High cost of national distribution
• Limited differentiation between private-label products
• Negative reviews driven by leakage or irritation

How much revenue exposure does Basic Care Tioconazole 1 have?

Brand-level revenue for Basic Care Tioconazole 1 is not publicly disclosed. The product is likely part of a broader private-label OTC portfolio rather than a separately reported business line.

Revenue sensitivity is driven by:

1. Retail distribution and search placement.
2. Price relative to branded one-dose products.
3. Seasonal demand for OTC vaginal antifungals.
4. Manufacturing cost per applicator.
5. Retailer margin requirements.
6. Repeat purchasing and consumer reviews.
7. Supply continuity.

Because the active ingredient is not exclusive, volume can move to an equivalent product quickly after a stockout, price increase, or quality complaint.

What licensing deals could create value?

Licensing opportunities are more likely to involve formulation technology, packaging, or manufacturing capability than tioconazole itself.

Potential deal structures include:

• Private-label supply agreements with retailers
• Contract manufacturing agreements
• Licensing of bioadhesive vaginal delivery systems
• Co-development of low-residue formulations
• Packaging licenses for unit-dose applicators
• Regional distribution agreements
• Portfolio licensing covering tioconazole, miconazole, and clotrimazole products

A formulation license would need to demonstrate a commercially meaningful advantage over the conventional oil-based product. Without comparative performance data, a new excipient system would have limited bargaining power.

What are the geographic opportunities?

The United States offers a relatively accessible OTC market because tioconazole vaginal products fit within the FDA monograph framework. International expansion is more complex because regulatory classification, labeling, permitted excipients, and prescription status vary by country.

Region	Commercial opportunity	Main barrier
United States	Private label and retail pharmacy	Price competition and monograph compliance
Canada	OTC or pharmacy-channel antifungal sales	Health Canada requirements
European Union	Vaginal antifungal market	Country-specific or centralized regulatory requirements
Latin America	Branded generic and pharmacy channels	Local registration and distributor dependence
Asia-Pacific	Large population and retail growth	Local regulatory, language, and channel requirements

A global excipient strategy should avoid relying on a preservative or packaging component that is accepted in the United States but restricted or treated differently in another jurisdiction.

Key Takeaways

• Basic Care Tioconazole 1 is a single-dose, 6.5% tioconazole vaginal ointment.
• The public formulation is based on mineral oil, purified water, and benzoic acid.
• The product has little meaningful active-ingredient or formulation exclusivity.
• Orange Book patent and Paragraph IV issues are generally not central because the product is marketed under the OTC monograph framework.
• Commercial differentiation is available through lower irritation, reduced leakage, improved applicators, water-based vehicles, and better packaging.
• The strongest potential patent claims would target measurable delivery or tolerability improvements, not conventional excipient combinations.
• Revenue is likely driven by private-label distribution, retailer economics, and manufacturing reliability rather than brand-level pricing power.
• Biosimilar risk is irrelevant because tioconazole is a small-molecule antifungal, not a biologic.
• Manufacturing quality, dose uniformity, preservation, and packaging compatibility are the principal technical barriers to entry.

FAQs

Is Basic Care Tioconazole 1 the same as Vagistat-1?

Both products use tioconazole 6.5% as a single-dose vaginal antifungal. Exact inactive ingredients, manufacturing controls, applicator design, and packaging may differ by manufacturer.

Can a company launch a competing tioconazole 1 product without waiting for patent expiration?

Generally yes, if the product complies with the applicable FDA OTC monograph, labeling requirements, and current good manufacturing practice rules. A competitor would not normally need to rely on an Orange Book Paragraph IV certification for a standard monograph product.

Are mineral oil vaginal formulations compatible with condoms?

Oil-based vaginal products can affect certain latex barrier products. Product-specific labeling should be followed, and compatibility should be assessed for the relevant condom or contraceptive material.

What is the most attractive excipient innovation for tioconazole 1?

A lower-residue, lower-irritation formulation with equal or better vaginal retention is the strongest commercial concept. It addresses a direct consumer complaint while creating a potential basis for differentiated claims.

Is tioconazole 1 a biosimilar product?

No. Tioconazole is a synthetic small-molecule drug. Competing products are generic or OTC monograph products, not biosimilars.

References

1. U.S. Food and Drug Administration. (2023). 21 C.F.R. Part 333, Subpart C: Antifungal drug products for over-the-counter human use. Electronic Code of Federal Regulations.

2. DailyMed. (n.d.). Tioconazole 6.5% vaginal ointment: Drug label. National Library of Medicine.

3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.